Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977468 · ClinicalTrials.gov registry record · Phase 1
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Eileen Connolly.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 3
- Study locations
NCT02977468: Recruiting Phase 1 study of Triple Negative Breast Cancer, sponsored by Eileen Connolly.
NCT02977468 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Eileen Connolly. The registered enrollment target is 15 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02977468, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Eileen Connolly.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 3
- Study locations
Study Summary
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Conditions Studied
Interventions
- DRUG Merck 3475 Pembrolizumab
- RADIATION Intraoperative radiation therapy (IORT)
Study Locations (3)
Georgia
- Emory University - Atlanta
Illinois
- Loyola University Chicago - Maywood
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT02977468 shows while recruiting
NCT02977468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Merck 3475 Pembrolizumab is the first listed.
NCT02977468 reports a single indexed study location in Georgia, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT02977468 about?
NCT02977468 is a clinical study titled "Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer". Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in n...
What is the current status of trial NCT02977468?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-10-25. Estimated completion is 2025-12-31.
What conditions does trial NCT02977468 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02977468?
The interventions under investigation include: Merck 3475 Pembrolizumab (DRUG), Intraoperative radiation therapy (IORT) (RADIATION).
Who is sponsoring clinical trial NCT02977468?
This trial is sponsored by Eileen Connolly, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977468 being conducted?
This trial has 3 study locations across Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02977468's enrollment target sits among peer trials
15 108th of 118 higher than 10 of 118 other Triple Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI